DNA Chip Research Institute

Basic Information

Stock Code
2397
Industry
Service Industry
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Tokyo
Establishment Year
April 1999
Listing Year
March 2004
Official Website
https://www.dna-chip.co.jp/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
Kojin Bio, Linical, Soft Front Holdings, Transgenic Group, ASJ, Shin Nihon Kagaku, All About, Auto Wave, Japan PrimeX, Techno Mathematical, MK System, Sugai Chemical Industry, H.U. Group Holdings, Falco Holdings, BML, Japan Pigment Research Institute, Toami, Human Metabolome Technologies, PhoenixBio

Overview

DNA Chip Research Institute is a specialist company in gene testing and analysis services founded in 1999, having established a solid position in the bio-pharmaceutical field centered on DNA chip technology and outsourced analysis services.

Current Situation

DNA Chip Research Institute recorded net sales of approximately 490 million yen and net assets of approximately 732 million yen for the fiscal year ended March 2024, maintaining a solid financial foundation. In its core gene analysis testing services, it collaborates with public research institutions and pharmaceutical companies to provide high-precision DNA chip technology. With support from Mitsui Chemicals following its subsidiary acquisition, it has strengthened its R&D structure, established a new research facility in Kawasaki City, and is working to expand services. In a competitive market environment, its unique chip development and outsourced analysis proposal capabilities serve as competitive advantages. Moving forward, it is pursuing a medium- to long-term strategy to expand clinical trial outsourcing and focus on bio-drug discovery fields, while actively promoting environmental burden reduction measures aligned with SDGs. Leveraging collaboration with Mitsui Chemicals, it is exploring the introduction of new gene-related technologies and service diversification. Aiming for revenue base diversification through digitalization対応 and customer base expansion. Recent capital increases and post-TOB shareholding by the parent company indicate stable business foundation.

Trivia

Interesting Facts

  • Specialized in DNA chip technology, contributing to Japan's bio industry for many years.
  • Technology development accelerated by support from Mitsui Chemicals.
  • Established latest medical laboratory in Kawasaki City.
  • Established position in the outsourced gene analysis service market.
  • Diverse product lineup for research institutions and pharmaceutical companies.
  • 37 employees, a lean elite technical team.
  • Listed on Mothers market in 2004, moved to TSE Second Section in 2014.
  • Continued technological innovation in DNA chips since early founding.
  • Early introduction of NGS analysis services, gaining lead.
  • High track record in regulatory compliance in clinical testing field.
  • Few major shareholders outside parent company, stable shareholder composition.
  • Also provides gene-related software analysis.
  • Developing new services through applied medical research.
  • One of the valuable bio genome analysis outsourcing companies.
  • Proven track record in providing custom DNA chips to researchers.

Hidden Connections

  • Leveraging capital ties with Mitsui Chemicals to advance fusion development of chemical and gene analysis technologies.
  • Participating in medical-related projects through cooperation with local Kawasaki City, Kanagawa Prefecture.
  • Accelerating technological innovation through joint development with public research institutions.
  • Proprietary fine chip fabrication technology that differentiates from competitors.
  • Strong network with domestic and international academic society members in DNA chip research field.
  • Contracts with multiple major pharmaceutical companies for clinical testing services in drug development.
  • Promoting cutting-edge research utilizing Mitsui Chemicals Group's research assets.
  • Ongoing plans to introduce AI analysis to support improved testing service precision.

Future Outlook

Growth Drivers

  • Increasing demand for bio-pharmaceuticals and drug discovery research.
  • Expansion of clinical testing outsourcing services.
  • Popularization of next-generation sequencing technology.
  • R&D strengthening through Mitsui Chemicals' capital support.
  • Advances in AI and bio-informatics analysis technologies.
  • Technology development considering environmental and ethical aspects.
  • Strengthened collaboration with domestic and international research institutions.
  • Improved competitiveness through new high-precision chip development.
  • Flexible response system to regulatory changes.
  • Service diversification tailored to customer needs.
  • Deployment of bioinformatics solutions.
  • Promotion of new projects through regional collaboration.

Strategic Goals

  • Expansion of market share in clinical testing outsourcing business.
  • Global expansion of gene analysis services.
  • Improvement in analysis precision and efficiency through AI utilization.
  • Business operations prioritizing environmental burden reduction.
  • Technological innovation through strengthened collaboration with Mitsui Chemicals Group.
  • Building a flexible service system responding to diverse customer needs.
  • Development and sales expansion of high value-added products.
  • Continuous R&D investment and开拓 of new fields.
  • Promotion of employee technical and business skill improvement.
  • Enhancement of social recognition and普及 of gene-related testing.

Business Segments

Gene Analysis Outsourcing Service

Overview
Supports research and development with outsourced analysis services using gene analysis technology.
Competitiveness
High-precision DNA chip technology and high reliability backed by Mitsui Chemicals support
Customers
  • Universities and public research institutions
  • Pharmaceutical companies
  • Biotechnology companies
  • Medical institutions
  • Drug discovery companies
  • Chemical manufacturers
  • Pharmaceutical research institutes
  • Medical labs
  • Clinical research institutions
  • New drug development companies
Products
  • DNA Chip Analysis
  • Gene Mapping Outsourcing
  • Microarray Platform
  • Bioinformatics Analysis
  • Clinical Trial Outsourcing Analysis
  • Research DNA Probes
  • Next-Generation Sequencing Analysis
  • Gene Profiling
  • Drug Discovery Support Services
  • Quality Control Standard Samples

DNA Chip Development and Sales

Overview
Development of high-precision DNA chip products and customized provision to meet customer needs.
Competitiveness
High-density and high-precision DNA chip manufacturing technology based on proprietary technology
Customers
  • University labs
  • Pharmaceutical manufacturers
  • Research institutions
  • Bio ventures
  • Corporate research institutes
  • Medical device manufacturers
  • Testing institutions
  • Drug discovery companies
Products
  • DNA Microarray Chips
  • Gene Testing Reagents
  • Standard DNA Probes
  • Custom Chip Design
  • Outsourced Manufacturing Services
  • Testing Equipment Compatible Chips

Clinical Testing and CRO Services

Overview
Outsourced clinical testing and clinical trial operations to support drug discovery development.
Competitiveness
Provision of regulatory compliance and high-quality analysis technology
Customers
  • Pharmaceutical companies
  • Medical institutions
  • Clinical trial outsourcing institutions
  • Bio companies
  • R&D departments
Products
  • Clinical Trial Testing Outsourcing
  • Clinical Trial Operation Support
  • CSO Services
  • SMO Operation Agency
  • Safety Testing

Bioinformatics Services

Overview
Provides advanced analysis of gene data and information management services.
Competitiveness
Data analysis capabilities by expert team
Customers
  • Pharmaceutical research institutes
  • Bio companies
  • University researchers
  • Medical institutions
Products
  • Gene Data Analysis
  • Bio Data Management
  • System Development
  • Analysis Software Provision

Medical and Research Reagent Sales

Overview
Provides gene-related reagents to meet diverse needs.
Competitiveness
Stable provision of diverse, high-quality reagents
Customers
  • University labs
  • Medical testing institutions
  • Pharmaceutical companies
  • Bio-related companies
Products
  • DNA Probes
  • Standard Reagents
  • Analysis Reagents
  • Gene-Related Reagents

Competitive Advantage

Strengths

  • High-precision DNA chip technology
  • High reliability in outsourced analysis
  • Strong capital support from Mitsui Chemicals
  • Presence of specialized technical staff
  • Strong ties with research institutions
  • Active investment in R&D
  • Sound financial base and healthy asset structure
  • Advanced bioinformatics analysis capabilities
  • Extensive experience in clinical testing
  • Flexible response to customer needs
  • Broad range of outsourcing services
  • Diverse deployment of gene-related products
  • High-quality reagent and product provision
  • Reliable regulatory compliance
  • Stable brand power in the industry

Competitive Advantages

  • High-precision analysis provision based on proprietary technology centered on DNA chips
  • Stable management backed by Mitsui Chemicals Group's capital and technical support
  • Long-term trusted relationships with research institutions and pharmaceutical companies
  • Deployment of high-quality and diverse outsourced analysis services
  • Regulatory response capabilities and reliability in clinical testing outsourcing services
  • Competitiveness of product lineup including microarrays
  • Differentiation through advanced bioinformatics analysis
  • Specialization in niche and specialized gene-related testing fields
  • Promotion of technological innovation through continuous R&D investment
  • Customized response to diverse customer needs
  • Revenue diversification through both outsourced analysis and product sales
  • Sustainable management enabled by strong financial base
  • Strengthened structure with latest research facility in Kawasaki City
  • Quality control system exceeding industry standards
  • Provision of finely segmented analysis menus not available from competitors

Threats

  • Risk of technological obsolescence due to rapid evolution of bio technologies
  • Decrease in outsourcing demand due to in-house development by major pharmaceutical companies
  • Intensifying price competition from peer competitors
  • Potential business constraints from regulatory changes
  • Market share decline due to new entrants
  • R&D investment reduction from decreased research funding
  • Competitive environment requiring balance of precision and cost
  • Difficulty in securing competitive edge in global markets
  • Cost burden for strengthening data security
  • Risks from external factors such as infectious disease outbreaks
  • Challenges in technology succession due to talent acquisition difficulties
  • Risk of changes in major shareholder management policies

Innovations

2025: Mitsui Chemicals Completes Tender Offer

Overview
Focusing on strengthening R&D and business expansion following parent company transition.
Impact
Achieved strengthening of capital base and management stabilization

2024: New Medical Laboratory Established in Kawasaki City

Overview
Introduced state-of-the-art equipment to expand outsourced analysis services.
Impact
Realized improved analysis precision and increased processing capacity

2024: Introduction of Automated System for Gene Analysis Services

Overview
Adopted robot technology to improve work efficiency and precision.
Impact
Reduced processing time by 50%, decreased human errors

2023: Launch of Next-Generation Sequencing Analysis Service

Overview
Started provision of advanced gene sequence analysis technology.
Impact
Successfully acquired new customers and expanded analysis needs

2022: Development of Gene Mapping Analysis Precision Enhancement Technology

Overview
Improved reliability and reproducibility of analysis through proprietary technology.
Impact
Received high evaluations from research institutions and pharmaceutical companies

Sustainability

  • Introduction of energy-saving equipment aimed at reducing environmental impact
  • Promotion of waste reduction programs in research processes
  • Participation in local cleanup activities and environmental education
  • Exploration and promotion of renewable energy use
  • Promotion of paper reduction through digitization of internal operations